Understanding hepatitis B, hepatitis C and HIV among people who inject drugs in South Africa: findings from a three-city cross-sectional survey.
Adult
Amphetamine-Related Disorders
/ epidemiology
Condoms
/ statistics & numerical data
Cross-Sectional Studies
Female
HIV Infections
/ epidemiology
HIV Seroprevalence
Harm Reduction
Health Policy
Hepatitis B Surface Antigens
/ immunology
Hepatitis B, Chronic
/ epidemiology
Hepatitis C Antibodies
/ immunology
Hepatitis C, Chronic
/ epidemiology
Heroin Dependence
/ epidemiology
Ill-Housed Persons
Humans
Male
Multivariate Analysis
Needle Sharing
/ statistics & numerical data
Needle-Exchange Programs
Opiate Substitution Treatment
Prevalence
Seroepidemiologic Studies
South Africa
/ epidemiology
Substance Abuse, Intravenous
/ epidemiology
Unsafe Sex
/ statistics & numerical data
Viral Load
HBV
HCV
HIV
Hepatitis B
Hepatitis C
Key populations
People who inject drugs
South Africa
Journal
Harm reduction journal
ISSN: 1477-7517
Titre abrégé: Harm Reduct J
Pays: England
ID NLM: 101153624
Informations de publication
Date de publication:
11 04 2019
11 04 2019
Historique:
received:
21
12
2018
accepted:
01
04
2019
entrez:
13
4
2019
pubmed:
13
4
2019
medline:
11
6
2020
Statut:
epublish
Résumé
People who inject drugs (PWID) are at high risk for hepatitis C (HCV), hepatitis B (HBV) and HIV without accessible harm reduction programmes. Coverage of needle and syringe and opioid substitution therapy (OST) services in South Africa is below global recommendations and no hepatitis services exist for PWID. We assessed HCV, HBV and HIV prevalence and risk factors among PWID accessing harm reduction services in Cape Town, Durban and Pretoria to inform policy and programming. We conducted a cross-sectional survey among PWID in these cities between August 2016 and October 2017. Participants were opportunistically sampled while accessing services. Study team members administered a questionnaire that assessed sociodemographic characteristics, drug use and sexual risk practices. We tested for HCV (antibody, viral load and genotype), HBV surface antigen (HBsAg) and HIV. Bivariate and multivariate analyses assessed associations with HCV serostatus. Nine hundred and forty-three PWID were included in the per protocol analysis. The majority (87%, 819/943) were male, the overall median age was 29 and most lived on the street (66%, 626/943). At last injection, 77% (722/943) reported using a new needle and syringe and 17% (163/943) shared equipment. HIV prevalence was 21% (196/926), HBsAg positivity 5% (47/936), HCV seroprevalence 55% (513/937), HCV viraemic prevalence (proportion tested with detectable HCV) 43% (404/937) and HCV viraemic rate (proportion HCV antibody positive with detectable HCV) 79% (404/513). HCV genotype 1a (73%, 270/368) was the most prevalent. In multivariate analysis, HCV infection was positively associated with residing in Pretoria (adjusted odds ratio (aOR) 1.27, 95% CI 1.21-1.34), living on the street (aOR 1.90, 95% CI 1.38-2.60), frequent injecting (aOR 1.58, 95% CI 1.15-2.16) and HIV infection (aOR 1.69, 95% CI 1.15-2.47), and negatively associated with black race (aOR 0.52, 95% CI 0.36-0.74) and sexual activity in the previous month (aOR 0.61, 95% CI 0.42-0.88). HCV and HIV are major health threats affecting PWID in these cities. Access to OST and needle and syringe services needs to be increased and integrated with HCV services. Social and structural factors affecting PWID who live on the street need to be addressed.
Sections du résumé
BACKGROUND
People who inject drugs (PWID) are at high risk for hepatitis C (HCV), hepatitis B (HBV) and HIV without accessible harm reduction programmes. Coverage of needle and syringe and opioid substitution therapy (OST) services in South Africa is below global recommendations and no hepatitis services exist for PWID. We assessed HCV, HBV and HIV prevalence and risk factors among PWID accessing harm reduction services in Cape Town, Durban and Pretoria to inform policy and programming.
METHODS
We conducted a cross-sectional survey among PWID in these cities between August 2016 and October 2017. Participants were opportunistically sampled while accessing services. Study team members administered a questionnaire that assessed sociodemographic characteristics, drug use and sexual risk practices. We tested for HCV (antibody, viral load and genotype), HBV surface antigen (HBsAg) and HIV. Bivariate and multivariate analyses assessed associations with HCV serostatus.
RESULTS
Nine hundred and forty-three PWID were included in the per protocol analysis. The majority (87%, 819/943) were male, the overall median age was 29 and most lived on the street (66%, 626/943). At last injection, 77% (722/943) reported using a new needle and syringe and 17% (163/943) shared equipment. HIV prevalence was 21% (196/926), HBsAg positivity 5% (47/936), HCV seroprevalence 55% (513/937), HCV viraemic prevalence (proportion tested with detectable HCV) 43% (404/937) and HCV viraemic rate (proportion HCV antibody positive with detectable HCV) 79% (404/513). HCV genotype 1a (73%, 270/368) was the most prevalent. In multivariate analysis, HCV infection was positively associated with residing in Pretoria (adjusted odds ratio (aOR) 1.27, 95% CI 1.21-1.34), living on the street (aOR 1.90, 95% CI 1.38-2.60), frequent injecting (aOR 1.58, 95% CI 1.15-2.16) and HIV infection (aOR 1.69, 95% CI 1.15-2.47), and negatively associated with black race (aOR 0.52, 95% CI 0.36-0.74) and sexual activity in the previous month (aOR 0.61, 95% CI 0.42-0.88).
CONCLUSIONS
HCV and HIV are major health threats affecting PWID in these cities. Access to OST and needle and syringe services needs to be increased and integrated with HCV services. Social and structural factors affecting PWID who live on the street need to be addressed.
Identifiants
pubmed: 30975139
doi: 10.1186/s12954-019-0298-2
pii: 10.1186/s12954-019-0298-2
pmc: PMC6460775
doi:
Substances chimiques
Hepatitis B Surface Antigens
0
Hepatitis C Antibodies
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
28Références
J Hepatol. 2016 Dec;65(6):1094-1103
pubmed: 27520879
AIDS Behav. 2013 Nov;17(9):2878-92
pubmed: 23975473
Drug Alcohol Depend. 2018 Sep 1;190:121-127
pubmed: 30014887
Drug Alcohol Depend. 2015 Nov 1;156:275-281
pubmed: 26460140
Int J Infect Dis. 2010 Dec;14(12):e1024-31
pubmed: 20870439
J Clin Virol. 2014 Sep;61(1):20-33
pubmed: 24973812
Harm Reduct J. 2017 Jun 7;14(1):35
pubmed: 28592246
PLoS One. 2014 Jul 28;9(7):e103345
pubmed: 25068274
Int J Epidemiol. 2011 Aug;40(4):885-901
pubmed: 21527446
S Afr Med J. 2017 Nov 27;107(12):1116-1120
pubmed: 29262967
Lancet. 2010 Jul 24;376(9737):268-84
pubmed: 20650523
Lancet Gastroenterol Hepatol. 2017 Dec;2(12):900-909
pubmed: 29132759
Drug Alcohol Depend. 2013 Oct 1;132(3):457-65
pubmed: 23578590
Harm Reduct J. 2013 Aug 19;10:13
pubmed: 23957896
Int J Drug Policy. 2016 Apr;30:107-15
pubmed: 26860326
Int J Drug Policy. 2016 Apr;30:43-51
pubmed: 26880500
PLoS One. 2014 Oct 06;9(10):e109282
pubmed: 25286346
Lancet Gastroenterol Hepatol. 2017 Dec;2(12):910-919
pubmed: 29132760
Vaccine. 2012 Sep 7;30 Suppl 3:C45-51
pubmed: 22939021
Lancet Glob Health. 2017 Dec;5(12):e1208-e1220
pubmed: 29074410
Harm Reduct J. 2013 May 07;10:7
pubmed: 23651646
S Afr Med J. 2018 Oct 02;108(10):800-802
pubmed: 30421704
J Viral Hepat. 2016 Nov;23(11):881-888
pubmed: 27545625
Cochrane Database Syst Rev. 2017 Sep 18;9:CD012021
pubmed: 28922449
Health (London). 2018 Jan;22(1):3-19
pubmed: 27491943
Lancet Glob Health. 2017 Dec;5(12):e1192-e1207
pubmed: 29074409